Neurocrine Biosciences | NBIX - Selling And Administration Expenses



Neurocrine Biosciences reported $286.3M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Acadia Pharmaceuticals USD 123.66M 2.71M Jun/2025
Agios Pharmaceuticals USD 45.87M 4.34M Jun/2025
ALKERMES USD 153.87M 17.83M Jun/2025
Alnylam Pharmaceuticals USD 323.31M 83.36M Jun/2025
Amgen USD 1.69B 4M Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
BioMarin Pharmaceutical USD 232.28M 26.16M Jun/2025
Cytokinetics USD 65.72M 8.35M Jun/2025
Dynavax Technologies USD 41.54M 64.79M Jun/2025
Exelixis USD 134.86M 2.32M Jul/2025
Gilead Sciences USD 1.36B 100M Jun/2025
Halozyme Therapeutics USD 33M 9.36M Jun/2025
Incyte USD 331.02M 5.33M Jun/2025
Ionis Pharmaceuticals USD 90.6M 14.6M Jun/2025
Neurocrine Biosciences USD 286.3M 9.8M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Prothena USD 15.91M 938K Jun/2025
Regeneron Pharmaceuticals USD 634.2M 1.2M Jun/2025
Repligen USD 71.23M 28K Jun/2025
Sarepta Therapeutics USD 69.89M 63.74M Jun/2025
Teva Pharmaceutical Industries USD 959M 40M Jun/2025
Ultragenyx Pharmaceutical USD 86.65M 1.15M Jun/2025
Vertex Pharmaceuticals USD 424.6M 28.2M Jun/2025